Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Treatment options for resectable stage III (N2) NSCLC have evolved rapidly over the last few years. However, an optimal treatment strategy has yet to be determined. In the below article, we present the results of LUN17-321 in the context of current treatment options available.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cllc.2025.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction: Results of the EXCELLENT Trial.
JACC Heart Fail
September 2025
Université de Lorraine, Inserm, Centre d'Investigations Cliniques Plurithématique 1433, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
Comparative effectiveness and safety of second-line therapies and dosing regimens for advanced hepatocellular carcinoma: a network meta-analysis.
Eur J Gastroenterol Hepatol
September 2025
Department of General Medicine, Affiliated Anqing First People's Hospital of Anhui Medical University, Anqing, Anhui, China.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated death globally. Second-line therapies are crucial for improving survival and quality of life among individuals suffering from advanced HCC who have not responded to first-line therapies. This study sought to evaluate the safety and efficacy of different second-line therapies for advanced HCC by network meta-analysis.
View Article and Find Full Text PDFBevacizumab for refractory gastrointestinal angiodysplasia: a case report and literature review.
Eur J Gastroenterol Hepatol
August 2025
Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar.
Currently, symptomatic gastrointestinal (GI) angiodysplasia is treated with argon plasma coagulation (APC) via endoscopic procedures, supplemented with octreotide or thalidomide treatment. However, suboptimal response and side effects are often seen. Bevacizumab, an angiogenesis inhibitor, may provide an alternative systemic therapy for patients with refractory GI angiodysplasia.
View Article and Find Full Text PDFSurgical options for correcting refractive surprise following lens and cataract surgery: a review and meta-analysis.
J Cataract Refract Surg
July 2025
Helsinki Retina Research Group, University of Helsinki, Finland.
Topic: To compare the outcomes of surgical approaches to correct ametropia following cataract and lens surgery.
Clinical Relevance: Despite advancements in the field of biometry and intraocular lens (IOL) power calculation formulas, complete elimination of refractive surprises following cataract and lens surgery is impossible. Preferred Practice Patterns acknowledges the possibility of refractive surprise following cataract surgery; however, no recommendations regarding the preferred treatment have been given.
The Use of Tranexamic Acid for Acute Abnormal Uterine Bleeding in the Emergency Department.
Adv Emerg Nurs J
September 2025
Author Affiliations: Emory University Hospital, Atlanta, Georgia (Drs Alvarez and Davis); and Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia (Dr Davis).
Acute abnormal uterine bleeding is a frequent reason for emergency department visits and, in severe cases, can become life-threatening. Tranexamic acid is a potential treatment option. However, its use in this setting remains under-researched.
View Article and Find Full Text PDF